Gemcitabine plus S‐1 vs S‐1
Overall response rate · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus S‐1 changes overall response rate compared with S‐1 (very low certainty).
1 finding from 1 review
- Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes onlyRR 2.46 [1.27, 4.75]2 studies · 140 participantsVery low